Ending the opioid epidemic requires addressing not only treatment gaps in addiction and overdose, but also inadequate pain management.
Resistant bacteria aren’t the only risk posed by overprescribing antibiotics. A more immediate risk is side-effects and reactions, which a new review shows are surprisingly frequent and often severe.
From expanding children’s coverage to reducing surprise bills, Biden and lawmakers may be able to broaden health care access.
When news reports tout a drug, people get interested, even if the benefits are unproven. Patient hopes, requests and demands can easily turn into real prescriptions in their doctor’s office.
Studies repeatedly have shown that health care in general and the high cost of drugs in particular are among the top concerns of US voters. But with coronavirus, the issue may fade from prominence.
To implement pharmacare, the Liberals will need to negotiate with the provinces, and the mostly Conservative premiers are unlikely to make this easy. The insurance industry also has much to lose.
When codeine became a prescription only drug in 2018, the number of overdoses dropped, our new research shows. But restricting sales of codeine is only one way to reduce harm from opioids.
The 1964 report that paved the way for Canada’s medicare envisaged that after universal coverage for doctors, the next step would be prescription drugs. But that next step hasn’t come.
Drug companies have a job to do and so does Health Canada. When the relationship becomes murky, the public are at risk.
Three-quarters of people with an intellectual disability receive prescribed drugs.
The collective public health of Canada, the United States and Mexico will take a hit if the new NAFTA becomes law.
Health Canada must be unbiased and it must be seen to be unbiased – so that Canadians get the best possible value out of prescription drugs.
Alarming rise in deaths from two prescription drugs sees them reclassified as class C.
A new study reveals how many patient groups lobby for new drugs to be funded by public plans in Canada – all while receiving funding from the companies manufacturing the drugs in question.
It takes about three years for safety problems to be identified in new drugs, newer drugs are almost always more expensive, and yet Canadian doctors still hand out hundreds of thousands of samples.
Two community pharmacists suggest a way for improving the palatability of evidence-based universal pharmacare – for those working in health insurance, pharmacy and the pharmaceutical industry.
Buyers think you can tell the purity of a substance by looking at on an app – evidence shows they’re mistaken.
Insurance companies sometimes try to cut costs by substituting less expensive drugs for a specific drug prescription. That’s raising problems in many cases, and actually causing harm.
Shortages and high prices are making pharmaceuticals, often including generics, out of reach for millions of Americans.
The medication landscape is complicated and error-riddled, with very few care providers knowing all the drugs you are taking. Here’s how pharmacists could be the solution.